$3.60
3.23% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US0396971071
Symbol
ARDX
Sector
Industry

Ardelyx, Inc. Stock price

$3.60
+0.21 6.19% 1M
-1.62 31.03% 6M
-1.47 28.99% YTD
-2.89 44.53% 1Y
-2.99 45.37% 5Y
-13.36 78.77% 10Y
-10.51 74.49% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.12 3.23%
ISIN
US0396971071
Symbol
ARDX
Sector
Industry

Key metrics

Market capitalization $861.32m
Enterprise Value $798.67m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.21
P/S ratio (TTM) P/S ratio 2.38
P/B ratio (TTM) P/B ratio 5.91
Revenue growth (TTM) Revenue growth 127.33%
Revenue (TTM) Revenue $361.71m
EBIT (operating result TTM) EBIT $-39.62m
Free Cash Flow (TTM) Free Cash Flow $-48.73m
Cash position $213.95m
EPS (TTM) EPS $-0.23
P/E forward negative
P/S forward 2.35
EV/Sales forward 2.18
Short interest 13.76%
Show more

Is Ardelyx, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Ardelyx, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Ardelyx, Inc. forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Ardelyx, Inc. forecast:

Buy
91%
Hold
9%

Financial data from Ardelyx, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
362 362
127% 127%
100%
- Direct Costs 56 56
138% 138%
15%
306 306
125% 125%
85%
- Selling and Administrative Expenses 289 289
80% 80%
80%
- Research and Development Expense 57 57
53% 53%
16%
-37 -37
38% 38%
-10%
- Depreciation and Amortization 2.23 2.23
29% 29%
1%
EBIT (Operating Income) EBIT -40 -40
36% 36%
-11%
Net Profit -54 -54
18% 18%
-15%

In millions USD.

Don't miss a Thing! We will send you all news about Ardelyx, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ardelyx, Inc. Stock News

Neutral
GlobeNewsWire
12 days ago
WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Kelliher, formerly Executive Vice President, Corporate Development and Strategy, has been promoted to Chief Business Offi...
Neutral
GlobeNewsWire
24 days ago
WALTHAM, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, President and CEO, will participate in a fireside chat at the Jefferies Global Healthcare Conference 2025 on Wednesd...
Neutral
GlobeNewsWire
about one month ago
Analysis of IBS in America 2024 Real-World Survey Demonstrates that severity of IBS-C correlates with financial hardship and distress Analysis of IBS in America 2024 Real-World Survey Demonstrates that severity of IBS-C correlates with financial hardship and distress
More Ardelyx, Inc. News

Company Profile

Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.

Head office United States
CEO Mike Raab
Employees 395
Founded 2007
Website www.ardelyx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today